(Q40326178)

19 September 2017

Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease (English)

1 reference

19 September 2017

1 reference

Francesca Pecori Giraldi

1

1 reference

19 September 2017

Carla Scaroni

2

1 reference

19 September 2017

Emanuela Arvat

3

1 reference

19 September 2017

Martina Martin

4

1 reference

19 September 2017

Roberta Giordano

5

1 reference

19 September 2017

Nora Albiger

6

1 reference

19 September 2017

Adriana A S Leao

7

1 reference

19 September 2017

Andreea Picu

8

1 reference

19 September 2017

Franco Mantero

9

1 reference

19 September 2017

Francesco Cavagnini

10

1 reference

19 September 2017

language of work or name

1 reference

1 February 2006

1 reference

19 September 2017

Clinical Endocrinology

1 reference

19 September 2017

64

1 reference

19 September 2017

2

1 reference

19 September 2017

219-224

1 reference

The medical treatment of Cushing's syndrome

19 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

Pre-operative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

Thiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta -hydroxysteroid dehydrogenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

Troglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

PPARgamma inhibits GH synthesis and secretion and increases apoptosis of pituitary GH-secreting adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

PPAR-gamma receptor ligands: novel therapy for pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2265.2006.02452.X

10.1111/J.1365-2265.2006.02452.X

21 January 2018

Identifiers

DOI

1 reference

19 September 2017

1 reference